Previous 10 | Next 10 |
2024-05-20 18:17:01 ET More on Larimar Therapeutics Seeking Alpha’s Quant Rating on Larimar Therapeutics Historical earnings data for Larimar Therapeutics Financial information for Larimar Therapeutics Read the full article on Seeking Alpha For...
2024-05-17 06:15:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips With innovation, millions of retiring baby boomers, demand for better care, patent cliffs, gene-editing, massive interest in weight-loss treatments, and an increase in mergers, biotech stocks...
2024-05-16 13:47:53 ET More on Biogen, Ionis Pharmaceuticals Biogen: Reasons To Be Cheerful After Upbeat Q1 Earnings Biogen: Don't Overthink This One Biogen and Ionis drop ALS candidate after trial setback Eisai projects major growth for Alzheimer's therapy L...
2024-05-16 09:00:18 ET More on Biogen, Ionis, etc. Ionis Pharmaceuticals, Inc. (IONS) Q1 2024 Earnings Call Transcript Biogen: Reasons To Be Cheerful After Upbeat Q1 Earnings Biogen: Don't Overthink This One Eisai projects major growth for Alzheimer's therapy...
Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire study Biogen and Ionis continue their long-standing commitment to developing therapies for ALS given the devastating impa...
2024-05-15 12:52:06 ET More on Eisai Eisai: All About Lenvima And Leqembi Biogen partner Eisai begins FDA submissions for injectable Alzheimer’s therapy Biogen’s Alzheimer's drug to cost $3.5B for Medicare in 2025: report Historical earnings dat...
2024-05-15 07:44:07 ET More on Biogen, Eisai Co., Ltd., etc. Biogen: Reasons To Be Cheerful After Upbeat Q1 Earnings Biogen: Don't Overthink This One Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade) Biogen says uptake for Alzheimer’s therapy...
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status PR Newswire TOKYO and CAMBRIDGE, Mass. , May 14, 2024...
2024-05-11 08:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The extraordinary performance of Nvidia (NASDAQ: NVDA ) in 2023 coincided with a seismic generative-AI rally that carried the entirety of the S&P 500 higher in a year th...
2024-05-09 06:30:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Here’s a question for you: What determines the value of a drug ? Is it the number of lives it saves or how much it costs to make? Is it the deadliness of the disease it prevents or t...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...